Cullinan Oncology (NASDAQ: CGEM) — Perfil da empresa, notícias e dados financeiros
Cullinan Oncology focuses on developing innovative cancer therapies to address unmet medical needs across diverse tumor types.

Cullinan Oncology
Cullinan Oncology (NASDAQ:CGEM) focuses on developing a broad pipeline of innovative cancer therapies aimed at addressing unmet medical needs across a wide range of tumor types. With operations grounded in a unique strategy that leverages its scientific expertise and technology platforms, Cullinan Oncology is actively engaged in pushing the boundaries of cancer treatment. The company's projects range from early discovery to clinical development stages, emphasizing a deep commitment to transforming cancer care. Objectives include accelerating the development of its pipeline through rigorous scientific research, fostering partnerships to enhance its capabilities, and ultimately improving patient outcomes in the oncology space.
Resumo
Operações
Produtos e/ou serviços de Cullinan Oncology
- CLN-081/TAS6417, a targeted therapy for non-small cell lung cancer with EGFR exon 20 insertion mutations.
- CLN-049, a FLT3 x CD3 bispecific antibody for acute myeloid leukemia.
- CLN-619, an MICA/B-targeted monoclonal antibody for solid tumors.
- CLN-617, a bispecific antibody targeting CD19 and CD3 for B-cell malignancies.
- CLN-978, a novel ADC targeting a Tn-MUC1 epitope for solid tumors.
- CLN-470, a next-generation covalent EGFR inhibitor for non-small cell lung cancer.
equipe executiva do Cullinan Oncology
- Nadim AhmedPresident, CEO & Director
- Mary Kay FentonChief Financial Officer
- Jeffrey JonesChief Medical Officer
- Patrick A. BaeuerleCo-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
- Jennifer MichaelsonChief Scientific Officer
- Nicholas SmithHead of Investor Relations
- Jacquelyn L. SumerChief Legal Officer, Chief Compliance Officer & Corporate Secretary
- Steve AndreChief Human Resources Officer
- Corinne SavillChief Business Officer
- Rose WeldonSenior Vice President of Corporate Affairs
Últimas notícias sobre a Cullinan Oncology
Cullinan reports 30.2% brain metastasis response with zipalertinib
United StatesCullinan starts FDA filing after 6-month PFS gain
United StatesCullinan zipalertinib improves PFS by six months
United StatesCullinan cancer drug trial meets Phase 3 endpoint
United StatesCullinan shares T-Cell engager data showing autoimmune remissions
United StatesCullinan Therapeutics secures FDA orphan drug designation for Leukemia candidate CLN-049
United States
Principais indicadores financeiros
Resultados divulgados pela Cullinan Oncology , em USD.
- Cap. de mercado
- 956,3 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -3.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -241,6 mi | -219,9 mi | |
| 0 | -196,9 mi | -167,4 mi | |
| 0 | -191,1 mi | -153,2 mi | |
| 0 | 144,6 mi | 111,2 mi |